TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid...

      

Related Stories

• Celgene Further Commits To Neuroscience With Prothena Pact
• Merger Buzz Boosts Shares Of India's Troubled Fortis
• Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

 

Original Article: TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

More From BioPortfolio on "TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients"